Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation

J Heart Lung Transplant. 2022 Sep;41(9):1214-1217. doi: 10.1016/j.healun.2022.05.017. Epub 2022 May 27.

¹ Hematology department and Biosurgical Research lab (Carpentier Foundation), Université de Paris, Innovative Therapies in Hemostasis, Georges Pompidou European Hospital, Paris, France. Electronic address: [email protected].
² Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
³ National Research Cardiac Surgery Center, Nur-Sultan, Kazakhstan.
⁴ Carmat SA, Velizy-Villacoublay, France.
⁵ Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark.
⁶ Cardiac and thoracic Surgery Department, CHU de Nantes, hôpital Nord Laënnec, boulevard Jacques-Monod, Saint-Herblain, France.
⁷ Department of Cardiac Surgery, Univ. Lille, CHU Lille, France.
⁸ Division of Cardiothoracic and Vascular Surgery, Pontchaillou University Hospital, Rennes, France.

No abstract available

Keywords: anticoagulation; low molecular weight heparin; total artificial heart.

Publication types